Walleye Trading’s Cytokinetics CYTK Stock Holding History

Walleye Trading’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$251K	Buy	+2,951	New	+$212K	﹤0.01%	3017
2026 Q1	–	Sell	-16,658	Closed	-$1.06M	–	4234
2025 Q4	$1.06M	Buy	16,658 +13,634	+451%	+$848K	﹤0.01%	2336
2025 Q3	$166K	Buy	+3,024	New	+$125K	﹤0.01%	3464
2024 Q1	–	Sell	-41,269	Closed	-$3.19M	–	4873
2023 Q4	$3.45M	Buy	+41,269	New	+$1.49M	0.01%	1493
2023 Q3	–	Sell	-15,066	Closed	-$502K	–	5054
2023 Q2	$491K	Buy	+15,066	New	+$557K	﹤0.01%	2762
2023 Q1	–	Sell	-11,514	Closed	-$528K	–	4922
2022 Q4	$528K	Buy	11,514 +5,550	+93%	+$239K	﹤0.01%	2764
2022 Q3	$289K	Buy	+5,964	New	+$287K	﹤0.01%	3393
2020 Q4	–	Sell	-11,979	Closed	-$259K	–	4658
2020 Q3	$259K	Buy	+11,979	New	+$280K	﹤0.01%	2796
2019 Q2	–	Sell	-10,100	Closed	-$97.4K	–	4113
2019 Q1	$82K	Buy	+10,100	New	+$74.3K	﹤0.01%	3545
2017 Q1	–	Sell	-800	Closed	-$10K	–	4748
2016 Q4	$10K	Buy	+800	New	+$8.49K	﹤0.01%	4304
2016 Q1	–	Sell	-3,200	Closed	-$33K	–	5398
2015 Q4	$33K	Sell	3,200 -1,400	-30%	-$13.7K	﹤0.01%	4135
2015 Q3	$31K	Buy	+4,600	New	+$31.4K	﹤0.01%	3816

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Trading's CYTK Position: Q2 2026 in Review

Walleye Trading opened a new position in Cytokinetics (CYTK) in Q2 2026: 2,951 shares worth $251K. The stake represents ﹤0.01% of the portfolio and ranks #3017 among its holdings. This is a return to the name: Walleye Trading previously reported a position in CYTK as recently as Q4 2025.

Walleye Trading first reported a position in CYTK in Q3 2015 and has held it in 12 quarters since. The position peaked at $3.45M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Walleye Trading held 2,951 shares of Cytokinetics worth $251K as of Q2 2026.
Cytokinetics was a new Walleye Trading position in Q2 2026.
Cytokinetics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #3017 holding.
Walleye Trading first reported a position in Cytokinetics in Q3 2015 and has held it in 12 quarters since.
Walleye Trading's Cytokinetics position peaked at $3.45M in Q4 2023.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.